Lentiviral Vectors as Catalysts for Vaccine Development

Jun 16, 2023

In the ever-evolving landscape of genetic research, lentiviral gene delivery has emerged as a powerful tool that has revolutionized the field of gene therapy and vaccine development. Lentiviral vectors (LVs), derived from HIV-1, have gained significant attention due to their unique ability to efficiently and stably transfer genetic material into both dividing and non-dividing cells. Particularly in the realms of infectious diseases and immuno-oncology, lentiviral vectors have gained substantial attention by effectively transducing dendritic cells (DCs) in vivo.

Recent studies have unveiled the ability of lentiviral vectors to induce endogenous gene expression of antigens within DCs, facilitating direct antigen presentation. This advantageous feature distinguishes lentiviral vectors from adenoviral vectors, eliminating the need for cross presentation and external antigen capture.

A study conducted in 2023 by Kirill Nemirov et al., demonstrated the remarkable capability of GFP lentiviral vectors, to transduce different subtypes of DCs in vivo, triggering the expansion of na?ve T cells². These subtypes include:

• Myeloid
  • CD11c⁺
  • CD11b⁺
  • CD8^?
• Lymphoid
  • CD11c⁺
  • CD11b^-
  • CD8⁺
• Plasmacytoid
  • CD11c^int
  • B220⁺

Excitingly, numerous clinical trials are currently underway, evaluating the therapeutic efficacy and safety of lentiviral-based gene therapy in the treatment of diseases such as ADA-SCID³?, as well as infectious diseases like Flavivirus, COVID-19, and Tuberculosis¹.

Lentiviral Solutions for Researchers

OriGene proudly offers a range of cutting-edge lentiviral products, providing researchers with the tools they need to unlock the full potential of this revolutionary technology and make strides towards a healthier future.

Lenti-ORF

Tagged Lenti ORF
clones and particles

Lenti-shRNA

Lentiviral shRNA
particles for gene
silencing

Lenti Accessories

From packaging kits
to transfection
reagents

Custom Lentivirus

Small and large-
scale production

CRISPR Vectors

For gRNA and Cas9
expression

Lentiviral Validation Data

2x10^{^}4 293T cells per well of 96-well plate were transduced with different volumes of Lenti-GFP particles (PS100071V: Lenti-C-mGFP) (3.5x10^{^}7 TU/ml). Particles were produced using Lenti-vpak packaging kit (TR30037). Fluorescent images were taken 72 hours post transduction.

View more Validation Data>>

Download our Lentivirus 101 E-book

Related Products

Premade AAV - ORF^? Particles

AAV Vectors

AAV Control Particles

AAV Antibodies

Related Services

AAV Packaging Service

Lentivirus Production Service

Transgene Knockin via CRISPR

Citations

1. Lundstrom K. Viral Vectors in Gene Therapy: Where Do We Stand in 2023? Viruses. 2023 Mar 7;15(3):698. doi: 10.3390/v15030698. PMID: 36992407; PMCID: PMC10059137.
2. Nemirov K, Bourgine M, Anna F, Wei Y, Charneau P, Majlessi L. Lentiviral Vectors as a Vaccine Platform against Infectious Diseases. Pharmaceutics. 2023 Mar 5;15(3):846. doi: 10.3390/pharmaceutics15030846. PMID: 36986707; PMCID: PMC10053212.
3. https://clinicaltrials.gov/ct2/show/NCT01380990